PT  - JOURNAL ARTICLE
AU  - ,
AU  - Kartsonaki, Christiana
TI  - Characteristics and outcomes of an international cohort of 400,000 hospitalised patients with Covid-19
AID  - 10.1101/2021.09.11.21263419
DP  - 2021 Jan 01
TA  - medRxiv
PG  - 2021.09.11.21263419
4099  - http://medrxiv.org/content/early/2021/09/21/2021.09.11.21263419.short
4100  - http://medrxiv.org/content/early/2021/09/21/2021.09.11.21263419.full
AB  - Background Policymakers need robust data to respond to the COVID-19 pandemic. We describe demographic features, treatments and clinical outcomes in the International Severe Acute Respiratory and emerging Infection Consortium (ISARIC) COVID-19 cohort, the world’s largest international, standardised cohort of hospitalised patients.Methods The dataset analysed includes COVID-19 patients hospitalised between January 2020 and May 2021. We investigated how symptoms on admission, comorbidities, risk factors, and treatments varied by age, sex, and other characteristics. We used Cox proportional hazards models to investigate associations between demographics, symptoms, comorbidities, and other factors with risk of death, admission to intensive care unit (ICU), and invasive mechanical ventilation (IMV).Findings 439,922 patients with laboratory-confirmed (91.7%) or clinically-diagnosed (8.3%) SARS-CoV-2 infection from 49 countries were enrolled. Age (adjusted hazard ratio [HR] per 10 years 1.49 [95% CI 1.49-1.50]) and male sex (1.26 [1.24-1.28]) were associated with a higher risk of death. Rates of admission to ICU and use of IMV increased with age up to age 60, then dropped. Symptoms, comorbidities, and treatments varied by age and had varied associations with clinical outcomes. Tuberculosis was associated with an 86% higher risk of death, and HIV with an 87% higher risk of death. Case fatality ratio varied by country partly due to differences in the clinical characteristics of recruited patients.Interpretation The size of our international database and the standardized data collection method makes this study a reliable and comprehensive international description of COVID-19 clinical features. This is a viable model to be applied to future epidemics.Funding UK Foreign, Commonwealth and Development Office, the Bill & Melinda Gates Foundation and Wellcome. See acknowledgements section for funders of sites that contributed data.Evidence before this study To identify large, international analyses of hospitalised COVID-19 patients that used standardised data collection, we conducted a systematic review of the literature from 1 Jan 2020 to 28 Apr 2020. We identified 78 studies, with data from 77,443 people (1) predominantly from China. We could not find any studies including data from low and middle-income countries. We repeated our search on 18 Aug 2021 but could not identify any further studies that met our inclusion criteria.Added value of this study Our study uses standardised clinical data collection to collect data from a vast number of patients across the world, including patients from low-, middle-, and high-income countries. The size of our database gives us great confidence in the accuracy of our descriptions of the global impact of COVID-19. We can confirm findings reported by smaller, country-specific studies and compare clinical data between countries. We have demonstrated that it is possible to collect large volumes of standardised clinical data during a pandemic of a novel acute respiratory infection. The results provide a valuable resource for present policymakers and future global health researchers.Implications of all the available evidence Presenting symptoms of SARS-CoV-2 infection in patients requiring hospitalisation are now well-described globally, with the most common being fever, cough, and shortness of breath. Other symptoms also commonly occur, including altered consciousness in older adults and gastrointestinal symptoms in younger patients, and age can influence the likelihood of a patient having symptoms that match one or more case definitions. There are geographic and temporal variations in the case fatality rate (CFR), but overall, CFR was 20.6% in this large international cohort of hospitalised patients with a median age of 60 years (IQR: 45 to 74 years).Competing Interest StatementPotential Conflict of interest: Allavena, C. declares personal fees from ViiVHealthcare, MSD, Janssen and Gilead, all outside the submitted work. Andrejak, C. declares personal fees for lecture from Astra Zeneca, outside the submitted work. Borie, R. declares personal fees for lecture from Roche, Sanofi and Boehringer Ingelheim, outside the submitted work Bosse, Hans Martin is co-investigator for placebo studies in infants and children in clinical trials by Actelion/Janssen (Johnson&Johnson), outside the submitted work Cheng, M. declares grants from McGill Interdisciplinary Initiative in Infection and Immunity, grants from Canadian Institutes of Health Research, during the conduct of the study; personal fees from GEn1E Lifesciences (as a member of the scientific advisory board), personal fees from nplex biosciences (as a member of the scientific advisory board), outside the submitted work. He is the co-founder of Kanvas Biosciences and owns equity in the company. In addition, M. Cheng reports a patent Methods for detecting tissue damage, graft versus host disease, and infections using cell-free DNA profiling pending, and a patent Methods for assessing the severity and progression of SARS-CoV-2 infections using cell-free DNA pending. Cholley, B. declares personal fees (for lectures and participation to advisory boards) from Edwards, Amomed, Nordic Pharma, and Orion Pharma. Claure-Del Granado, R. declares personal fees (for lectures and participation to advisory boards) from Nova Biomedical, Medtronic, and Baxter all outside the submitted work. Cruz-Bermudez, J.L. declares personal fees from Elsevier for advice, outside the submitted work. Cummings, M. and O Donnell, M. participated as investigators for clinical trials evaluating the efficacy and safety of remdesivir (sponsored by Gilead Sciences) and convalescent plasma (sponsored by Amazon) in hospitalized patients with COVID-19. Support for this work is paid to Columbia University. Dalton, H. declares personal fees for medical director of Innovative ECMO Concepts and honorarium from Abiomed/BREETHE Oxi-1 and Instrumentation Labs. Consultant fee, Entegrion Inc. Deplanque, D. declares personal fees from Biocodex, Bristol-Myers Squibb and Pfizer (advisory boards) Donnelly, C.A. declares research funding from the UK Medical Research Council and the UK National Institute for Health Research. Dudman, S. reports grants from Research Council of Norway grant no 312780. Durante-Mangoni, E. declares funding via his Institution from MSD, Pfizer, and personal fees or participation in advisory boards or participation to the speaker bureau of Roche, Pfizer, MSD, Angelini, Correvio, Nordic Pharma, Bio-Merieux, Abbvie, Sanofi-Aventis, Medtronic, Tyrx and DiaSorin. Dyrhol-Riise, AM, declares grants from Gilead outside this work. Grasselli, G. declares personal fees from Getinge, Biotest, Draeger Medical, Fisher & Paykel, MSD and unrestricted research grant from MSD and Fisher & Paykel, all outside the submitted work. Guerguerian AM. Participated as site investigator for the Hospital For Sick Children, Toronto, Canada as a site through SPRINT-SARI Study via the Canadian Critical Care Trials Group sponsored in part by the Canadian Institutes of Health Research. Ho, A. declares grant funding from Medical Research Council UK, Scottish Funding Council - Grand Challenges Research Fund, and the Wellcome Trust, outside this submitted work. Holter, J. C. reports grants from Research Council of Norway grant no 312780, and from Vivaldi Invest A/S owned by Jon Stephenson von Tetzchner, during the conduct of the study. Kimmoun, A. declares personal fees (payment for lectures) from Baxter, Aguettant, Aspen. Kumar, D. declares grants and personal fees from Roche, GSK and Merck; and personal fees from Pfizer and Sanofi. Kutsogiannis, D.J. declares personal fees for a lecture from Tabuk Pharmaceuticals and the Saudi Critical Care Society Kutsyna, G. declares the study consulting fee for clinical trial ClinicalTrials.gov Identifier: NCT04762628 Laffey, J. reports that he has received fees for consultancy from GlaxoSmithKline and from Baxter Therapeutics for work outside the scope of this work. Lairez, O. declares grant funding from Pfizer; conference fees from Amicus, GE Healthcare, Novartis, Sanofi-Genzyme, and Takeda-Shire; and consultancy fees from Alnylam, Amicus, Pfizer, Takeda-Shire. Lee, J. reports grants from European Commission PREPARE grant agreement No 602525, European Commission RECOVER Grant Agreement No 101003589 and European Commission ECRAID-Plan Grant Agreement 825715 supporting the conduct, coordination and management of the work. Lee, T.C. declares research salary support from les Fonds de recherche du Quebec - Sante. Lefevre, B. declares travel/accommodation/meeting expenses from Mylan and Gilead, all outside the submitted work. Lellouche, F. declares grants from CIHR for COVID-19 studies, is co-founder and administrator of Oxynov.inc, fees from Fisher&Paykel, Vygon and Novus Lemaignen, A. declares personal fees (payment for lectures) from MSD and Gilead; and travel/accommodation/meeting expenses from Pfizer. Leone, M declares personal fees from Gilead, MSD, Aspen, Ambu and Amomed Lescure, F.X. declares personal fees (payment for lectures) from Gilead, MSD; and travel/accommodation/meeting expenses from Astellas, Eumedica, MSD. Liu, K. reports personal fees from MERA and receives a salary from TXP Medical completely outside the submitted work. Martin-Blondel G declares support for attending meetings and personal fees from BMS, MSD, Janssen, Sanofi, Pfizer and Gilead for lectures outside the submitted work. Martin-Loeches I. declared lectures for Gilead, Thermofisher, Pfizer, MSD; advisory board participation for Fresenius Kabi, Advanz Pharma, Gilead, Accelerate, Merck; and consulting fees for Gilead outside of the submitted work. Martin-Quiros, A. declares consulting fees for Gilead. Mentre F, declares consulting fees from IPSEN, Servier and Da Volterra, and reports research grants to her group from Sanofi, Roche, Servier and Da Voleterra, all outside the submitted work. Montrucchio, G declares personal fees for lecture from Pfizer, Gilead outside the submitted work. Murthy, S declares receiving salary support from the Health Research Foundation and Innovative Medicines Canada Chair in Pandemic Preparedness Research. Nichol, A. declares a grant from the Health Research Board of Ireland to support data collection in Ireland (CTN-2014-012). Openshaw, P. has served on scientific advisory boards for Janssen/J&J, Oxford Immunotech Ltd, GSK, Nestle and Pfizer (fees to Imperial College). He is Imperial College lead investigator on EMINENT, a consortium funded by the MRC and GSK. He is a member of the RSV Consortium in Europe (RESCEU) and Inno4Vac, Innovative Medicines Initiatives (IMI) from the European Union. Peltan, I.D. declares grant support from the National Institutes of Health and, outside the submitted work, grant support from Centers for Disease Control and Prevention, and Jannsen and payments to his institution for trials by Regeneron and Asahi Kasei Pharma on which he served as an investigator. Pesenti, A. declares personal fees from Maquet, Novalung/Xenios, Baxter, and Boehringer Ingelheim. Peytavin G., declares consulting fees (for lectures and/or participation in advisory boards) and travel grants from Gilead Sciences, Janssen, Merck, Takeda, Theratechnologies, and ViiV Healthcare. Poissy, J. declares personal fees from Gilead for lectures, outside the submitting work Povoa, P. declares personal fees (for lectures and advisory boards) from MSD, Technophage, Sanofi, and Gilead. Povoas, D. declares consulting fees (for lectures and/or participation in advisory boards) from Roche and Viiv Healthcare; and travel/accommodation/meeting expenses from Abbvie, Gilead Sciences, Janssen Cilag, Merck Sharp & Dohme and ViiV Healthcare Rewa, O. declares consulting fees from Baxter Inc. Rossanese, A. declares consulting fees (for lectures and/or participation to advisory boards) from Emergent BioSolutions and Sanofi Pasteur, but all outside of the frame of the submitted work. Sandulescu, O. has been an investigator in COVID-19 clinical trials by Algernon Pharmaceuticals, Atea Pharmaceuticals, Regeneron Pharmaceuticals, Diffusion Pharmaceuticals, and Celltrion, Inc., outside the scope of the submitted work. Semple, M.G. reports grants from DHSC National Institute of Health Research UK, from the Medical Research Council UK, and from the Health Protection Research Unit in Emerging & Zoonotic Infections, University of Liverpool, supporting the conduct of the study; other interest in Integrum Scientific LLC, Greensboro, NC, USA, outside the submitted work. Serpa Neto, A. declares personal lecture fees from Drager outside the submitted work. Shrapnel, S. participated as an investigator for an observational study analysing ICU patients with COVID-19 (for the Critical Care Consortium including ECMOCARD) funded by The Prince Charles Hospital Foundation during the conduct of this study. S. Shrapnel reports in kind support from the Australian Research Council Centre of Excellence for Engineered Quantum Systems (CE170100009). Streinu-Cercel, Adrian has been an investigator in COVID-19 clinical trials by Algernon Pharmaceuticals, Atea Pharmaceuticals, Regeneron Pharmaceuticals, Diffusion Pharmaceuticals, and Celltrion, Inc., outside the scope of the submitted work. Streinu-Cercel, Anca has been an investigator in COVID-19 clinical trials by Algernon Pharmaceuticals, Atea Pharmaceuticals, Regeneron Pharmaceuticals, Diffusion Pharmaceuticals, and Celltrion, Inc., outside the scope of the submitted work. Summers, C. reports that she has received fees for consultancy for Abbvie relating to COVID-19 therapeutics. She was also the UK Chief Investigator of a GlaxoSmithKline plc sponsored study of a therapy for COVID, and is a member of the UK COVID Therapeutic Advisory Panel (UK-CTAP). Outside the scope of this work, Dr Summers institution receives research grants from the Wellcome Trust, UKRI/MRC, National Institute for Health Research (NIHR), GlaxoSmithKline and AstraZeneca to support research in her laboratory. Tedder, R. reports grants from MRC/UKRI during the conduct of the study. In addition, R. Tedder has a patent United Kingdom Patent Application No. 2014047.1 SARS-CoV-2 antibody detection assay issued. Terzi, N. reports personal fees from Pfizer, outside the submitted work. JF Timsit participated in an advisory board for MSD, Pfizer, nabriva, Gilead, Shionoghi, Medimune outside the submitted work; personal fees from Merck, Pfizer, Gilead, Beckton dickinson, Medimune, Bayer pharma; lecture fees from MSD, Biomerieux, Pfizer, Shionoghi; and research grants to his research unit from Pfizerpers, Merck, Thermofisher. Turtle, L. reports grants from MRC/UKRI during the conduct of the study and fees from Eisai for delivering a lecture related to COVID-19 and cancer, paid to the University of Liverpool. Ullrich, R. reports grant funding to his institution from Apeptico, APEIRON, Biotest, Bayer, CCORE and Philips, as well as personal fees from Biotest. He holds European patent EP15189777.4 Blood purification device and equity in CCORE Technology GesmbH, a medical device research and development company. Visseaux B. declares personal fees from BioMerieux, Qiagen and Gilead and research grants from Qiagen, all outside the submitted work. West, E. reports grant funding from the Firland Foundation, the US CDC, and the Bill and Melinda Gates Foundation for studies of COVID-19, and grant funding from the US NIH for studies of other respiratory infections. Funding StatementThis work was made possible by the UK Foreign, Commonwealth and Development Office; Wellcome [215091/Z/18/Z] [205228/Z/16/Z] [220757/Z/20/Z]; Bill & Melinda Gates Foundation [OPP1209135]; CIHR Coronavirus Rapid Research Funding Opportunity OV2170359 and the coordination in Canada by Sunnybrook Research Institute; endorsement of the Irish Critical Care- Clinical Trials Group, co-ordination in Ireland by the Irish Critical Care- Clinical Trials Network at University College Dublin and funding by the Health Research Board of Ireland [CTN-2014-12]; the Rapid European COVID-19 Emergency Response research (RECOVER) [H2020 project 101003589] and European Clinical Research Alliance on Infectious Diseases (ECRAID) [965313]; the COVID clinical management team, AIIMS, Rishikesh, India; Cambridge NIHR Biomedical Research Centre; the dedication and hard work of the Groote Schuur Hospital Covid ICU Team; support by the Groote Schuur nursing and University of Cape Town registrar bodies coordinated by the Division of Critical Care at the University of Cape Town; the Liverpool School of Tropical Medicine and the University of Oxford; the dedication and hard work of the Norwegian SARS-CoV-2 study team; the Research Council of Norway grant no 312780, and a philanthropic donation from Vivaldi Invest A/S owned by Jon Stephenson von Tetzchner; Imperial NIHR Biomedical Research Centre; Innovative Medicines Initiative Joint Undertaking under Grant Agreement No. 115523 COMBACTE, resources of which are composed of financial contribution from the European Unions Seventh Framework Programme (FP7/2007- 2013) and EFPIA companies, in-kind contribution; Stiftungsfonds zur Forderung der Bekampfung der Tuberkulose und anderer Lungenkrankheiten of the City of Vienna, Project Number: APCOV22BGM; Italian Ministry of Health Fondi Ricerca corrente-L1P6 to IRCCS Ospedale Sacro Cuore-Don Calabria; Australian Department of Health grant (3273191); Gender Equity Strategic Fund at University of Queensland, Artificial Intelligence for Pandemics (A14PAN) at University of Queensland, the Australian Research Council Centre of Excellence for Engineered Quantum Systems (EQUS, CE170100009), the Prince Charles Hospital Foundation, Australia; and preparedness work conducted by the Short Period Incidence Study of Severe Acute Respiratory Infection. This work uses Data / Material provided by patients and collected by the NHS as part of their care and support #DataSavesLives. The Data / Material used for this research were obtained from ISARIC4C. The COVID-19 Clinical Information Network (CO-CIN) data was collated by ISARIC4C Investigators. Data and Material provision was supported by grants from: the National Institute for Health Research (NIHR; award CO-CIN-01), the Medical Research Council (MRC; grant MC_PC_19059), and by the NIHR Health Protection Research Unit (HPRU) in Emerging and Zoonotic Infections at University of Liverpool in partnership with Public Health England (PHE), (award 200907), NIHR HPRU in Respiratory Infections at Imperial College London with PHE (award 200927), Liverpool Experimental Cancer Medicine Centre (grant C18616/A25153), NIHR Biomedical Research Centre at Imperial College London (award IS-BRC-1215-20013), and NIHR Clinical Research Network providing infrastructure support. Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethics Committee approval was given by the WHO Ethics Review Committee (RPC571 and RPC572, 25 April 2013). Institutional approval was additionally obtained by participating sites including the South Central - Oxford C Research Ethics Committee in England (Ref 13/SC/0149), the Scotland A Research Ethics Committee (Ref 20/SS/0028) for the UK, which represents the majority of the data. Other institutional and national approvals are in place as per local requirements.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData sharing The ISARIC-WHO Clinical Characterisation Protocol, case report form and consent forms are openly available on the ISARIC website at https://isaric.org/research/covid-19-clinical-research-resources/clinical-characterisation-protocol-ccp/. The statistical analysis plan is openly available on the ISARIC website at https://isaric.org/research/covid-19-clinical-research-resources/accessing-covid-19-clinical-data/approved-uses-of-platform-data/ Most individual patient data are available to researchers approved by the Data Access Committee. The data inventory, application form and terms of access for the COVID-19 Data Platform, hosted by the Infectious Diseases Data Observatory (IDDO), are available at https://www.iddo.org/covid19/data-sharing/accessing-data. All individual participant data are available to individuals from sites who have contributed to the ISARIC COVID-19 Platform via the ISARIC Partner Analysis Scheme. See details via this link: https://isaric.org/research/isaric-partner-analysis-frequently-asked-questions/